Interpreting Laboratory Test Results in the United States and the United Kingdom

Interpreting Laboratory Test Results in the United States and the United Kingdom: What Truly Differs—and Where Errors Most Often Occur

1) Context: the difference is rarely “biology”; it is the interpretive infrastructure

A laboratory result is not simply a number. It is a number plus its units, measurement method, calibration traceability, reference interval, clinical decision threshold, and reporting conventions. In practice, the most consequential US–UK differences arise in these interpretive layers rather than in the analyte itself.

Common pitfalls include:
• the same analyte reported in different units (e.g., mg/dL vs mmol/L; g/dL vs g/L);
• different analytical platforms and calculation algorithms (notably for eGFR);
• clinical decisions anchored to national guidance (NICE/NHS practice in the UK; professional societies and federal regulatory frameworks in the US), with action thresholds that may not be identical.

2) The regulatory “quality frame”: CLIA (US) versus UKAS/ISO 15189 (UK)

United States: CLIA as the mandatory baseline
In the US, the baseline regulatory framework for clinical laboratory quality is CLIA (Clinical Laboratory Improvement Amendments). CLIA is a federal regime intended to ensure the accuracy and reliability of patient test results used for diagnosis, prevention, or treatment. (1,2)

Practically, CLIA focuses on laboratory processes, personnel requirements, quality systems, and performance oversight (including proficiency testing). It does not impose a single national set of reference intervals for all laboratories; reference intervals are validated and implemented at the laboratory and method level within accepted professional standards and local verification practices. (1,2)

United Kingdom: emphasis on competence accreditation (ISO 15189 via UKAS)
In the UK, medical laboratories are commonly accredited to ISO 15189 through UKAS. ISO 15189 accreditation underpins confidence in laboratory competence, impartiality, and quality management processes. (3,4)

For interpretation, this typically supports a more uniform quality ecosystem; nevertheless, method- and population-related variation in reference intervals and reporting conventions still exists, and results remain method- and laboratory-context dependent.

Working conclusion (both countries): a result can be interpreted correctly only within the context of the specific laboratory report (method, units, reference interval, and any interpretive comments), and then mapped to the relevant national clinical guidance.


3) Units of measurement: the most frequent source of clinical misunderstanding

UK: SI units as the default
Most routine testing in the UK is reported in SI units (e.g., mmol/L, µmol/L, g/L, ×10⁹/L). UK laboratory services explicitly describe reference ranges and interpretive limitations in SI-based reporting. (5,6)

US: durable coexistence of “conventional” units
In US clinical practice, conventional units remain widely used (e.g., glucose mg/dL; creatinine mg/dL; cholesterol mg/dL). In research and regulatory contexts, SI units may be required or presented in parallel. The FDA explicitly acknowledges this duality: SI units are the worldwide standard, while many US healthcare providers are trained using US conventional units, which often convey the most clinical meaning in US practice. (7)

As an illustration of accepted parallel reporting, CDC editorial guidance notes that when both SI and conventional units are presented, the value may be repeated in parentheses with the alternate unit. (8,9)

Critical error: comparing numbers without converting units. For example, glucose 5.6 mmol/L (typical UK SI reporting) is approximately 101 mg/dL (common US reporting). Without conversion, a normal value may be misread as dangerously high or implausibly low.


4) Reference intervals: “normal” is not universal—and is not required to be identical

UK laboratory services explicitly state that reference ranges are conventionally set to capture approximately 95% of a statistically “normal” population, and they warn that ranges may not account for factors such as ethnic variation or differences between venous and capillary samples. (5,6)

A practical consequence is that the same result may be flagged “H” or “L” in one laboratory and fall within the reference interval in another, particularly near decision boundaries.

A professional rule (valid in both the US and UK):
1. first, read the reference interval and any interpretive comments from that laboratory report;
2. then compare the result to clinical decision thresholds and targets in the applicable national guideline.


5) Guideline thresholds: where differences are most visible in day-to-day practice

5.1 HbA1c: IFCC (mmol/mol) in the UK versus NGSP (%) in the US

In the UK, NICE guidance commonly expresses HbA1c in mmol/mol (IFCC standard) and often provides a percent equivalent. (10) In the US, HbA1c reporting frequently remains in NGSP (%) units; NGSP materials state that the US will continue reporting HbA1c as % (NGSP numbers), consistent with recommendations from US professional organizations. (11)

This is not a superficial difference. Clinicians trained to think in percent may perceive trends and thresholds differently from those accustomed to mmol/mol—especially near intervention cutoffs. Official conversion tools exist to harmonize interpretation across units. (11)

International HbA1c standardization is also a well-documented example of how harmonization reduces inter-method and inter-laboratory variability; the evolution and impact of NGSP standardization are described in peer-reviewed literature. (12)


5.2 eGFR: a calculated estimate—and the “race-free” transition (CKD-EPI 2009 vs 2021)

In the US, the adoption of CKD-EPI 2021 (race-free) equations has been a major trend. NIDDK provides calculators, equations, and implementation considerations using race-free CKD-EPI formulas. (13,14)

In the UK, NICE NG203 provides the clinical framework for CKD assessment and management, including risk stratification and referral decisions. (15) However, professional guidance has emphasized that the choice of eGFR equation can materially affect downstream risk tools. For example, UK Kidney Association communications on the Kidney Failure Risk Equation (KFRE) highlight equation compatibility issues and caution regarding substituting eGFR equations in tools that were calibrated using specific methods. (16)

Practical conclusion: eGFR is not a directly measured analyte; it is a modeled estimate. Interpretation requires knowing:
• which equation was used by the laboratory/reporting system;
• the creatinine units and calibration traceability assumptions embedded in the lab method and equation implementation;
• which national guideline and risk tool is being applied downstream (and whether that tool is validated for the eGFR method used). (13–16)


5.3 Lipids: the UK emphasis on non-HDL cholesterol response

In the UK, NICE NG238 states that for primary prevention the aim is a greater than 40% reduction in non-HDL cholesterol with statin therapy. (17) This shifts interpretive emphasis toward treatment response (percentage reduction) rather than focusing exclusively on an absolute LDL-C value, with follow-up testing at specified intervals in guidance and local pathways.

In the US, lipid management is frequently embedded in risk-based decision frameworks; for example, USPSTF recommendations for primary prevention consider age, risk factors, and estimated 10-year CVD risk when deciding on statin initiation. (18)

Summary: UK lipid interpretation is often “response-based” (non-HDL-C reduction), whereas US interpretation is frequently “risk-based” (eligibility and intensity guided by estimated event risk and risk factors).


5.4 Cardiac troponins: hs-cTn as a standard—and the necessity of assay-specific thresholds

In the US, the 2021 AHA/ACC chest pain guideline recognizes high-sensitivity cardiac troponins as the preferred standard for establishing a biomarker diagnosis of acute myocardial infarction, enabling more efficient clinical decision pathways. (19) Peer-reviewed analyses further emphasize that myocardial injury is defined using the assay-specific 99th percentile upper reference limit, reinforcing the need for platform- and assay-specific interpretation. (20)

In the UK, NICE NG185 provides the framework for early and longer-term management of acute coronary syndromes. (21)

Key methodological point (both countries): troponin “cutoffs” are assay-dependent, typically anchored to the 99th percentile for the specific test, and integrated into serial sampling protocols. Transposing a numeric value across platforms or systems without method awareness is clinically unsafe.


6) Preanalytics and reporting: why the “same patient” can yield different numbers

Even with excellent analytical performance, results vary due to preanalytical factors such as:
• time of sampling (e.g., cortisol, iron indices, some hormones);
• posture, tourniquet time, hydration status;
• fasting versus non-fasting state (relevant for parts of lipid and metabolic testing);
• sample type (venous vs capillary blood)—UK laboratory services explicitly note that reference ranges may not account for such differences. (5)

In the UK, patient portals often display automated flags, but laboratory services simultaneously stress that “universal norms” are limited and context-dependent. (5,6) In the US, variability can be amplified by the breadth of the private laboratory sector and the diversity of methods across laboratory networks; switching laboratories can turn yesterday’s “normal” into today’s “abnormal” without a meaningful clinical change.

A practical interpretation workflow that works in both the US and the UK

1. Verify units (SI vs conventional) and convert when necessary. (7–9)
2. Confirm method/platform—especially for hs-troponin, hormones, vitamin D assays, HbA1c, and coagulation testing. (12,19,20)
3. Use the reference interval and interpretive comments from the reporting laboratory—not generic tables. (5,6)
4. Distinguish reference intervals from clinical action thresholds; take treatment targets and decision triggers from national guidance (NICE in the UK; US guideline/regulatory context and professional recommendations). (10,15,17–21)
5. For modeled values (eGFR), identify the equation and ensure downstream risk tools are validated for that implementation. (13–16)

Reviewed by clinical advisors.
11.01.2026
Developed with input from clinical experts and laboratory partners
Educational content. Not a substitute for professional medical advice.


References
1.Centers for Medicare & Medicaid Services (CMS). Research Testing and Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations (PDF, v.12/10/2014). Available from: https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/research-testing-and-clia.pdf  
2.CMS. Clinical Laboratory Improvement Amendments (CLIA). Available from: https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments  
3.UK Accreditation Service (UKAS). Medical Laboratory Accreditation – ISO 15189. Available from: https://www.ukas.com/accreditation/standards/medical-laboratory-accreditation/  
4.UKAS. ISO 15189:2022 transition arrangements. Available from: https://www.ukas.com/accreditation/iso-15189-transition/  
5.Manchester University NHS Foundation Trust. Reference ranges (Haematology). Available from: https://mft.nhs.uk/the-trust/other-departments/laboratory-medicine/haematology/reference-ranges/  
6.Manchester University NHS Foundation Trust. Reference ranges (Biochemistry). Available from: https://mft.nhs.uk/the-trust/other-departments/laboratory-medicine/biochemistry/reference-ranges/  
7.U.S. Food and Drug Administration (FDA). CDER/CBER Position on Use of SI Units for Lab Tests (Oct 25, 2013) (PDF). Available from: https://www.fda.gov/media/161520/download  
8.CDC. Emerging Infectious Diseases—Units of Measure. Available from: https://wwwnc.cdc.gov/eid/page/units-of-measure  
9.CDC. Emerging Infectious Diseases Editorial Style Guide (PDF). Available from: https://wwwnc.cdc.gov/eid/pdfs/styleguide.pdf  
10.National Institute for Health and Care Excellence (NICE). NG28: Type 2 diabetes in adults: management—Recommendations. Available from: https://www.nice.org.uk/guidance/ng28/chapter/recommendations  
11.NGSP. IFCC Standardization of HbA1c (IFCC–NGSP harmonization). Available from: https://ngsp.org/ifccngsp.asp  
12.Little RR, Rohlfing CL, Sacks DB. The NGSP: Over 20 Years of Improving HbA1c Measurement. Clin Chem. 2019. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6693326/  
13.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Estimated Glomerular Filtration Rate (eGFR) Calculators. Available from: https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/kidney-disease/laboratory-evaluation/estimated-gfr-calculators  
14.NIDDK. eGFR Equations for Adults. Available from: https://www.niddk.nih.gov/research-funding/research-programs/kidney-clinical-research-epidemiology/laboratory/glomerular-filtration-rate-equations/adults  
15.NICE. NG203: Chronic kidney disease: assessment and management. Available from: https://www.nice.org.uk/guidance/ng203  
16.UK Kidney Association. Adoption of the Kidney Failure Risk Equation. Available from: https://www.ukkidney.org/about-us/news/adoption-kidney-failure-risk-equation  
17.NICE. NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification—Recommendations. Available from: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations  
18.U.S. Preventive Services Task Force (USPSTF). Statin Use in Adults: Preventive Medication. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication  
19.Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029  
20.Sandoval Y, et al. High-Sensitivity Cardiac Troponin and the 2021 AHA/ACC/… Chest Pain Guidelines. Circulation. 2022. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059678  
21.NICE. NG185: Acute coronary syndromes—Recommendations. Available from: https://www.nice.org.uk/guidance/ng185/chapter/Recommendations